Scholar Rock Holding Corporatio (SRRK) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $46.02: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 32.19; Below-average business quality.
Scholar Rock is a pre-commercial biopharmaceutical company developing anti-myostatin antibodies for rare neuromuscular diseases, led by apitegromab for spinal muscular atrophy (SMA). The company submitted a BLA to the FDA in January 2025 but received a Complete Response Letter... Read more
Sell if holding. Engine safety override at $46.02: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 32.19; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.3/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductapitegromab10-K Item 1A: 'We have never commercialized a product and are in the process of building and scaling our business for potential commercialization of apitegromab in the United States and Europe'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $46.02: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 32.19; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $43.89. Score 4.3/10, moderate confidence.
Take-profit target: $51.96 (+13.0% upside). Prior stop was $43.89. Stop-loss: $43.89.
Concentration risk — Product: apitegromab; Quality below floor (1.7 < 4.0).
Scholar Rock Holding Corporatio trades at a P/E of N/A (forward -21.6). TrendMatrix value score: 6.0/10. Verdict: Sell.
22 analysts cover SRRK with a consensus score of 4.4/5. Average price target: $58.
What does Scholar Rock Holding Corporatio do?Scholar Rock is a pre-commercial biopharmaceutical company developing anti-myostatin antibodies for rare neuromuscular...
Scholar Rock is a pre-commercial biopharmaceutical company developing anti-myostatin antibodies for rare neuromuscular diseases, led by apitegromab for spinal muscular atrophy (SMA). The company submitted a BLA to the FDA in January 2025 but received a Complete Response Letter in September 2025 due to a third-party fill-finish facility GMP deficiency, delaying potential US commercialization.